Innovate Retina

Presented by the Stanford Byers Eye Institute

2024 dates will be announced soon!

Register

Join Us!

Virtually – TBD

Live – Thursday, October 17, 2024 – Chicago

Location
TBD

Agenda at a glance
3:30 PM – 4:00 PM – Registration, Exhibits and Light Snacks
4:00 PM – 5:00 PM – General Session
5:00 PM – 5:30 PM – Break, Exhibits and Dinner
5:30PM – 7:00 PM – General Session
7:00 PM – 7:30 PM – Dessert and Reception

 

Overview

Retina Innovate focuses exclusively on game-changing innovations in medical and surgical retina care, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology, and the latest advances in retinal pharmacotherapy.

FACULTY

Discussion Highlights

Topics will include late breaking retina pharmacotherapy clinical trials data, current management of neovascular AMD, diabetic macular edema, and diabetic retinopathy, updates on artificial intelligence (AI) for diagnosis, advances in molecular surgery for the precision treatment of previously untreatable blinding diseases, and novel drug delivery technologies designed to improve patient care. We will also focus on the role of imaging in determining new biomarkers for disease. Surgical innovation will be addressed in terms of new instrumentation, visualization enhancements, and image–guided surgery.

AGENDA

Educational Objectives

  • Identify current management practices for common retinal vascular diseases. 
  • Discuss how to diagnose and treat ocular inflammation as an adverse event in the management of retinal vascular diseases. 
  • Recognize how management strategies can mitigate the burden of retinal vascular disease.  
  • Assess innovations across imaging, medical devices, artificial intelligence, and pharmacotherapeutics. 
  • Examine the latest clinical data on emerging pharmacotherapeutics in the retina. 
  • Evaluate novel surgical imaging systems. 
  • Explain how to manage macular edema secondary to ocular inflammation employing local and/or systemic therapy. 
  • Identify therapies in development for uveitis and ocular inflammatory diseases. 

Target Audience

Practicing retina specialists, retinal fellows in training, and vitreoretinal surgeons. Comprehensive ophthalmologists, vision and AI scientists in retina, translational scientists, oncologists and allied physicians, and imaging experts are encouraged to attend.